MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/130/0.1/20.12.24

MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/130/0.1/20.12.24 Share Price

DE000MB3P3G8

Real-time Bid/Ask 09:09:53 30/05/2024 BST
0.018 ^EUR / 0.04 ^EUR	+45.00%

Current month	-9.09%
1 month	-9.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/130/0.1/20.12.24

Latest news about GILEAD SCIENCES, INC.

Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies against Novel Targets and Target Pairs	05-29	AQ
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024	05-22	BU
Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	05-20	AQ
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	05-18	BU

More news

Quotes 5-day view

Date	Price	Change
30/05/24	0.018	-10.00%
29/05/24	0.02	0.00%
28/05/24	0.02	+11.11%
27/05/24	0.018	-18.18%
24/05/24	0.022	0.00%

Delayed Quote Börse Stuttgart

Last update May 30, 2024 at 08:53 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Morgan Stanley
WKN	MB3P3G
ISIN	DE000MB3P3G8
Date issued	15/02/2023
Strike	130 $
Maturity	20/12/2024 (205 Days)
Parity	10 : 1
Emission price	0.23 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.37 €
Lowest since issue	0.015 €
Spread	0.022 €
Spread %	55.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

63.5 USD

Average target price

82.77 USD

Spread / Average Target

+30.35%

Consensus